

**ASX ANNOUNCEMENT****ADMEDUS'S CARDIOCEL® CLEARED FOR SALE IN THE US**

- CardioCel® now able to be marketed in the US
- Adds to EU approval in 2013
- Platform for growth in revenue for Admedus

**Brisbane, Australia, 10th February 2014**

Admedus (ASX: AHZ) today announced it has received FDA clearance to market CardioCel® in the US. CardioCel® is the group's lead regenerative tissue product to repair and treat a range of cardiovascular and vascular defects. The Company will now look to complement its existing product launch in Europe with preparation for initial sales in the US.

The intended use of CardioCel® in the US is in pericardial closure and for the repair of cardiac and vascular defects in both adults and paediatrics.

"This is a significant milestone for the Company as we expand into global markets and further develop our range of regenerative tissue products for commercialisation and sale." said Mr. Lee Rodne, CEO of Admedus Ltd.

"CardioCel® is an important addition to the surgeon's armoury in the treatment of congenital heart disease, as well as for the repair of heart valves and other cardiac defects" he said.

Admedus is able to sell CardioCel® in both Europe and the US and will pursue market approvals in Asia and other jurisdictions.

"Admedus is looking forward to an exciting 2014/15 as we launch CardioCel® globally and continue to grow our sales revenue and cardiovascular teams in these regions" said Mr Rodne.

CardioCel® is engineered by the group's ADAPT® tissue engineering process to be a durable, pure collagen scaffold that avoids calcification, supports native cell infiltration, growth and differentiation and which promotes a regenerative healing process.

CardioCel® has shown benefits over existing products in that it does not calcify like other tissue products and has shown to facilitate autologous tissue regeneration once surgically implanted, while retaining strength and natural elasticity. CardioCel® is a ready to use, off the shelf product that has the potential to prevent follow up surgeries for patients because of its anti-calcification and regenerative properties.

Admedus will be attending the 14<sup>th</sup> Annual International Symposium on Congenital Heart Disease on the 14<sup>th</sup> of February in Florida.

This program has been supported with a grant from Commercialisation Australia, funded by the Australian government.

**For more information, please contact:**

Dr. Julian Chick, Chief Operating Officer Admedus Limited Tel: +61 3 9620 5454

Media:

Rebecca Wilson

Buchan Consulting

+61 39866 4722

[rwilson@buchanwe.com.au](mailto:rwilson@buchanwe.com.au)

**About Admedus Limited**

Admedus (ASX: AHZ) is a diversified healthcare company focused on investing in and developing next generation technologies with world class partners, acquiring strategic assets to grow its product and service offerings and expanding revenues from its existing profitable medical sales and distribution business. The Company has assets from research & development through clinical development as well as sales, marketing and distribution.

Admedus is in the process of commercialising its innovative tissue engineering technology for regenerative medicine. Admedus also has a major interest in developing the next generation of vaccines with a Brisbane-based research group led by Professor Ian Frazer. The vaccine programs target disease with significant global potential such as Herpes and Human Papillomavirus.

Further information on the Company can be found on [www.admedus.com](http://www.admedus.com)

**Admedus Regen**

Admedus Regen started as a research program in 2001 focusing on tissue engineering and regenerative medicine based around the proprietary ADAPT<sup>®</sup> Tissue Engineering Process. The lead program, CardioCel<sup>®</sup> is approved in Europe and is being used in Australia under the Authorised Prescriber Scheme. CardioCel<sup>®</sup> is a cardiovascular scaffold used to repair paediatric and adult heart deformities. These deformities range from routine "hole in the heart" operations to major vessel outflow tract repairs. The CardioCel<sup>®</sup> scaffold may also be used to repair leaking heart valves in paediatric and adult patients. CardioCel<sup>®</sup> has been shown to allow tissue regeneration once implanted. Some researchers postulate that stem cells play an active role in tissue regeneration\*, suggesting that CardioCel<sup>®</sup> facilitates endogenous stem cells and other cells to regenerate and repair damaged tissue.

The division is based on the patented ADAPT<sup>®</sup> Tissue Engineering Process as a platform technology to produce implantable tissue scaffolds for use in various soft tissue repair applications and for the production of replacement tissue heart valves. The ADAPT<sup>®</sup> technology is used to process xenograft tissues to produce unique implantable tissue scaffolds that are compatible with the human body. The technology has a number of advantages over current tissue treatment processes on the market, most notably the reduction of calcification post implantation and has the potential to replace many of the products that surgeons currently use for soft tissue repair.

\* Körbling&Estrov, 2003. Adult Stem Cells for Tissue Repair — A New Therapeutic Concept? NEJM Volume 349:570-582, August 7, 2003, Number 6